Janus Henderson Group
ENGN icon

Janus Henderson Group’s enGene Therapeutics ENGN Stock Holding History

Janus Henderson Group’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,900,000
Closed -$17.1M – 2428
2025
Q4 		$17.1M Buy
+1,900,000
New +$15.2M 0.01% 639
2024
Q4 		– Sell
-1,000,000
Closed -$6.63M – 2547
2024
Q3 		$6.63M Hold
1,000,000
– – ﹤0.01% 789
2024
Q2 		$9.04M Hold
1,000,000
– – ﹤0.01% 690
2024
Q1 		$17.1M Buy
+1,000,000
New +$12.2M 0.01% 586

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Janus Henderson Group's ENGN Position: Q1 2026 in Review

Janus Henderson Group sold out of enGene Therapeutics (ENGN) in Q1 2026, closing a stake of 1,900,000 shares — an estimated $17.1M sold.

Janus Henderson Group first reported a position in ENGN in Q1 2024 and held it in 4 quarters. The position peaked at $17.1M in Q4 2025. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

  • Janus Henderson Group reported no remaining enGene Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Janus Henderson Group sold 1,900,000 enGene Therapeutics shares in Q1 2026, an estimated $17.1M.
  • Janus Henderson Group first reported a position in enGene Therapeutics in Q1 2024 and held it in 4 quarters.
  • Janus Henderson Group's enGene Therapeutics position peaked at $17.1M in Q4 2025.
  • 61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.